Verona Pharma plc
VRNA
Ранг среди акций
#2196
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Цена акции
$106.91
Последняя синхронизация: 2025-10-07
Рыночная капитализация
$9.09B
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
GB
Торговля Verona Pharma plc (VRNA)
Категория
Healthcare
История цены акций Verona Pharma plc (VRNA)
Наивысшая цена закрытия: $106.85 2025-10-01
Наименьшая цена закрытия: $13.50 2017-04-01
Наименьшая цена закрытия: $13.50 2017-04-01
История цены акций Verona Pharma plc с 2017 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2025 | 154.19% |
| 2024 | 157.60% |
| 2023 | -2.67% |
| 2022 | 215.71% |
| 2021 | -30.29% |
| 2020 | 68.43% |
| 2019 | -55.34% |
| 2018 | -13.21% |
| 2017 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
